---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-101342"
form_type: "8-K"
ticker: "RZLT"
cik: "0001509261"
company_name: "Rezolute, Inc."
filed_at: "2024-09-19T23:59:59+00:00"
generated_at: "2026-05-31T03:36:05.845507+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rezolute reports Q4 FY2024 net loss of $23M; FDA lifts partial clinical hold on ersodetug

## Summary
- Q4 net loss $23.0M vs $12.7M prior year; full year net loss $68.5M vs $51.8M.
- Cash and investments $127.1M at June 30, 2024, up from $118.4M year-over-year.
- FDA lifts partial clinical holds on ersodetug for congenital HI; U.S. enrollment in Phase 3 sunRIZE expected early 2025.
- Phase 3 study for tumor HI to begin H1 2025; topline results expected mid-2026.
- Phase 2 RZ402 for DME met primary endpoints; partnering discussions ongoing.

## SEC filing metadata
- accession: 0001104659-24-101342
- form_type: 8-K
- ticker: RZLT
- cik: 0001509261
- company_name: Rezolute, Inc.
- filed_at: 2024-09-19T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509261/000110465924101342/0001104659-24-101342-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509261/000110465924101342/tm2424269d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-101342
- JSON: https://secwatch.observer/filing/0001104659-24-101342.json
- Plain text: https://secwatch.observer/filing/0001104659-24-101342.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.